Portman Ltd’s Pulmonx LUNG Stock Holding History

Portman Ltd’s Portfolio LUNG Stock Details LUNG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-41,905	Closed	-$534K	–	8
2023 Q4	$534K	Buy	+41,905	New	+$437K	0.6%	8

Other funds holding LUNG

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Portman Ltd's LUNG Position: Q1 2024 in Review

Portman Ltd sold out of Pulmonx (LUNG) in Q1 2024, closing a stake of 41,905 shares — an estimated $534K sold.

Portman Ltd first reported a position in LUNG in Q4 2023 and held it in 1 quarter. The position peaked at $534K in Q4 2023. 118 funds tracked by Wall St. Rank hold LUNG as of Q1 2024.

Portman Ltd reported no remaining Pulmonx position as of Q1 2024 after selling out during the quarter.
Portman Ltd sold 41,905 Pulmonx shares in Q1 2024, an estimated $534K.
Portman Ltd first reported a position in Pulmonx in Q4 2023 and held it in 1 quarter.
Portman Ltd's Pulmonx position peaked at $534K in Q4 2023.
118 funds tracked by Wall St. Rank held Pulmonx as of Q1 2024.

Based on Portman Ltd's 13F filing for Q1 2024, filed 14 May 2024.